Download Files:
Rodatristat ethyl
$920 – $7,500
Products Details
Product Description
– Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH)[1][2].
Web ID
– HY-101124
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C29H31ClF3N5O3
References
– [1]Aiello RJ, et al. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Modelsof Pulmonary Hypertension. J Pharmacol Exp Ther. 2017 Feb;360(2):267-279.|[2]Alice Melão, MSc. Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients. FEBRUARY 4, 2019.
CAS Number
– 1673571-51-1
Molecular Weight
– 590.04
Compound Purity
– 98.04
SMILES
– ClC1=CC(C2=CC=CC=C2)=C([C@@H](OC3=NC(N)=NC(N4CCC5(CN[C@H](C(OCC)=O)C5)CC4)=C3)C(F)(F)F)C=C1
Clinical Information
– Phase 2
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– 5-HT Receptor;Tryptophan Hydroxylase
Isoform
– 5-HT1 Receptor
Pathway
– GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
